Skip to main content
. Author manuscript; available in PMC: 2018 Jun 29.
Published in final edited form as: Cancer Cell. 2016 Apr 11;29(4):494–507. doi: 10.1016/j.ccell.2016.03.006

Figure 3. cIAP1/2 participate in chronic active BCR signaling in ABC DLBCL.

Figure 3

(A) Immunoprecipitation (IP) from ABC DLBCL lines using the indicated antibodies were immunoblotted for the indicated proteins. (B) Relative luciferase activity of an IκBα-luciferase fusion protein in TMD8 cells treated with birinapant (5µM) for 6 hours and then with an anti-IgM antibody (10 µg/ml) for the indicated times. Reporter activity was normalized to values from DMSO-treated samples at time zero. Error bars denote SEM of triplicates. p values (Student’s t test) compare treatment groups with the DMSO control; ** p < 0.01. (C) SDS lysates of the indicated lines were subjected to biotin-labeled K63-specific TUBE binding, streptavidin purification. TUBE-purified proteins or total lysates were analyzed by immunoblotting. (D) ABC DLBCL lines were induced to express a CD79A or control (Ctrl.) shRNA. SDS lysates were mixed with biotin-labeled, K63-specific or K48-specific TUBEs followed by streptavidin purification. TUBE-purified proteins or total lysates were analyzed by immunoblotting. (E) SDS (1%) lysates prepared from DLBCL lines treated with the indicated SMAC mimetics (5 µM) for 24 hours, diluted and subjected to anti-BCL10 IP. IPs or total lysates were analyzed by immunoblotting. See also Figure S3.